Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice

Robrecht Thoonen1,2,†, Anje Cauwels1,2, Kelly Decaluwe3, Sandra Geschka4, Robert E. Tainsh5, Joris Delanghe6, Tino Hochepied1,2, Lode De Cauwer1,2, Elke Rogge1,2, Sofie Voet1,2, Patrick Sips1,2, Richard H. Karas7, Kenneth D. Bloch5, Marnik Vuylsteke8,9, Johannes-Peter Stasch4,10, Johan Van de Voorde3, Emmanuel S. Buys5,* & Peter Brouckaert1,2,*

Oxidative stress, a central mediator of cardiovascular disease, results in loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by nitric oxide (NO). Here we introduce Apo-sGC mice expressing haem-free sGC. Apo-sGC mice are viable and develop hypertension. The haemodynamic effects of NO are abolished, but those of the sGC activator cinaciguat are enhanced in apo-sGC mice, suggesting that the effects of NO on smooth muscle relaxation, blood pressure regulation and inhibition of platelet aggregation require sGC activation by NO. Tumour necrosis factor (TNF)-induced hypotension and mortality are preserved in apo-sGC mice, indicating that pathways other than sGC signalling mediate the cardiovascular collapse in shock. Apo-sGC mice allow for differentiation between sGC-dependent and -independent NO effects and between haem-dependent and -independent sGC effects. Apo-sGC mice represent a unique experimental platform to study the in vivo consequences of sGC oxidation and the therapeutic potential of sGC activators.
Oxidative stress is a risk factor for cardiovascular disorders\textsuperscript{1–2}. Oxidative stress interferes with the nitric oxide (NO)/soluble guanylate cyclase (sGC)/3',5'-cyclic guanosine monophosphate (cGMP) pathway\textsuperscript{1–3}, critical for cardiovascular and platelet function. First, reactive oxygen species can uncouple nitric oxide synthase (NOS), resulting in the production of superoxide (O$_2^-$) instead of NO. Second, O$_2^-$ scavenges NO, decreasing its bioavailability. Third, oxidative stress impairs the sensitivity of sGC for NO\textsuperscript{4}. sGC is a heterodimeric haemoprotein, consisting of an $\alpha_1$ or $\alpha_2$ subunit combined with a common $\beta_1$ subunit, which generates cGMP. Basal catalytic activity of sGC is greatly enhanced upon binding of NO to the ferrous haem, disrupting the bond between the haem and the HIS105 residue of sGC\textsubscript{$\beta_1$} (ref. 5). Although sGC is considered as the principal target of NO, this paradigm has been challenged by the discovery of signalling pathways involving protein nitrosylation\textsuperscript{6}. Oxidation of the ferrous haem, associated with haem-dissociation in vitro, results in the generation of haem-free sGC (apo-sGC), which has preserved basal activity but can no longer be activated by NO\textsuperscript{7,8}. In vivo, apo-sGC has been shown to be susceptible to ubiquitination and subsequent proteasomal breakdown\textsuperscript{9}. Levels of apo-sGC are hypothesized to be increased in conditions of oxidative stress in vivo\textsuperscript{10–12}.

The development of drugs targeting apo-sGC represents a unique approach to treat pathologies characterized by oxidative stress and associated with impaired cGMP signalling. Two classes of drugs modulating sGC activity exist: NO-independent, haem-dependent sGC stimulators, such as BAY 41-2272 and riociguat (Adempas or BAY 63-2521)\textsuperscript{13}, and NO- and haem-independent sGC activators, such as cinaciguat (BAY 58-2667) and atacigau (HMRI766)\textsuperscript{14,15}. The therapeutic potential of riociguat was recently illustrated in phase III clinical trials for the treatment of pulmonary arterial hypertension (PAH)\textsuperscript{13} and subsequent Food and Drug Administration approval for PAH treatment. However, the inability to distinguish native, haem-containing sGC from oxidized/haem-free sGC\textsuperscript{8} in vivo has precluded investigations into the specific pathological consequences of impaired sGC activity through haem-oxidation in vivo, as well as the consequences of specifically activating the oxidized/haem-free pool of sGC in vivo. To provide a scientific basis for the concept of targeting apo-sGC as a pharmacological strategy, we generated mice expressing haem-free sGC (apo-sGC mice) instead of native sGC, by mutation of the HIS105 residue of sGC\textsubscript{$\beta_1$} to PHE105.

Here, we report the in vivo cardiovascular phenotype of apo-sGC mice, identifying activation of haem-containing reduced sGC as the essential mechanism by which NO induces vasorelaxation, lowers blood pressure (BP) and inhibits platelet aggregation. Our data suggest that SGC activators, a new class of drugs in development for the treatment of a variety of cardiovascular diseases, can attenuate haemodynamic abnormalities associated with oxidative stress. In addition, apo-sGC mice allow to distinguish between sGC-dependent effects and sGC-independent effects of NO, such as nitrosylation, and to discriminate between haem-dependent and haem-independent effects of sGC. For example, the role of NO-sGC signalling in the potentially lethal cardiovascular collapse associated with overwhelming systemic inflammation is controversial. Septic or inflammatory shock remains the primary cause of death in intensive care units\textsuperscript{16} and NO signalling is considered a central pathway of the cardiovascular collapse associated with the resulting systemic shock. The prevailing paradigm identifies sGC as a central mediator leading to hypotension, shock and mortality in systemic inflammation\textsuperscript{17,18}. To test this paradigm, we measured BP, HR and mortality in TNF-induced systemic shock in apo-sGC and wild-type (WT) mice. Our findings that apo-sGC mice are not protected from the cardiovascular collapse and lethality associated with TNF-induced systemic shock, indicate that sGC is not a central mediator of hypotension, shock and mortality in systemic shock.

**Results**

**Generation of apo-sGC mice.** Apo-sGC mice were generated using standard transgenic methods using a targeting strategy designed so that the WT exon 5 of the endogenous Gucy1b3 gene was replaced with a mutant exon 5 carrying the H105F point mutation, resulting in replacement of the WT histidine, which is responsible for ligation of the haem-group to sGC\textsuperscript{6}, with a phenylalanine (Supplementary Fig. 1a). Analysis of progeny showed that mice heterozygous (HE) and homozygous knock-in (KI) for the knock-in mutation were viable but with a skewed Mendelian segregation in the offspring of HE breeders at 21 days of life (27% WT ($n = 1,172$), 51% HE ($n = 2,252$), 22% apo-sGC ($n = 987$); $\chi^2 = 17.5; P < 0.001$).

**Molecular characterization of apo-sGC mice.** mRNA expression levels of transcripts for sGCx1, sGCx2 and sGC$\beta_1$ protein were similar in the brain, the kidney, the lung and the left ventricle of apo-sGC (KI), HE, and WT mice (Fig. 1a), indicating that introduction of the H105F mutation in sGC$\beta_1$ does not affect expression of sGC subunits. Similarly, no changes were observed in the expression of genes encoding other relevant proteins in the NO/cGMP signalling pathway (Supplementary Fig. 2). In contrast to the similar gene expression levels in the different genotypes, sGCx1, sGCx2 and sGC$\beta_1$ protein levels were lower in tissues of apo-sGC and HE mice than in WT mice (Fig. 1b and Supplementary Fig. 3). Basal cGMP levels in tissues did not differ between apo-sGC, HE and WT mice (Fig. 1c). Baseline sGC activity was similar in lung and aorta homogenates of apo-sGC and WT mice (Fig. 1d,e). The ability of the NO-donor compound diethylthiocarbamylamine NO (DETA-NO) to increase cGMP levels in vivo was attenuated and absent in aortas of HE or apo-sGC mice, respectively (Fig. 1c). Similarly, DETA-NO was unable to increase sGC activity in tissue extracts from the lung and the aorta of apo-sGC mice (Fig. 1d,e). In contrast, cinaciguat, a haem-independent sGC activator, activated sGC in apo-sGC tissue extracts (Fig. 1d,e).

**Apo-sGC enzyme function in CHO cells.** The combined observation of reduced sGC protein levels together with preserved basal cGMP levels suggests that the apo-sGC enzyme has a higher basal activity than the WT enzyme. To test this hypothesis, we assessed apo-sGC enzyme function in vitro in a cGMP reporter cell line. Basal cGMP production was higher in reporter cells expressing haem-free sGC\textsubscript{$\beta_1$}H105F than in cells expressing WT-sGC (Fig. 2a).

In reporter cells expressing WT, haem-containing sGC, cGMP production was increased in a concentration-dependent manner by cinaciguat (Fig. 2b). Adding the selective sGC inhibitor 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), which exerts its activity through oxidation of the haem, enhanced the ability of cinaciguat to activate sGC (Fig. 2b). Stimulation with BAY 41-2272 increased cGMP synthesis in a concentration-dependent manner (Fig. 2c). Combination of BAY 41-2272 with 1 nmol l$^{-1}$ diethylamine NONOate (DEA/NO) synergistically stimulated sGC (Fig. 2c).

In reporter cells expressing apo-sGC, cinaciguat increased the activity of apo-sGC (Fig. 2d) in a dose-dependent manner. Addition of 10 $\mu$M ODQ did not enhance cinaciguat-induced sGC activity (Fig. 2d). In contrast, neither BAY 41-2272 alone at concentrations previously demonstrated to specifically activate sGC but not inhibit phosphodiesterase (PDE) activity nor BAY
41-2272 in combination with NO was able to activate apo-sGC (Fig. 2e). These data indicate that the activity of apo-sGC is higher than WT sGC at baseline and that apo-sGC can concentration dependently be activated by haem-independent sGC activators but not by haem-dependent sGC stimulators.

**Impaired NO-mediated platelet inhibition in apo-sGC mice.** Tail bleeding time, an in vivo measure of platelet reactivity, was shorter in apo-sGC mice than in WT littermates (Fig. 3a). In addition, platelet activation studies were performed on isolated platelets of WT and apo-sGC mice by measuring the ability of an NO donor compound (sodium nitroprusside (SNP)) to modulate thrombin-induced surface expression of CD62P. Although stimulation of platelets with thrombin resulted in a similar upregulation of CD62P on WT and apo-sGC platelets, SNP inhibited CD62P expression on WT but not apo-sGC platelets (Fig. 3b). Together, these data demonstrate that inhibition of platelet activation is impaired in apo-sGC mice, suggesting that the ability of NO to inhibit platelet activation critically depends on sGC.

**Haemodynamic response to NO is absent in apo-sGC mice.** We next investigated the in vivo impact of oxidized sGC on cardiovascular function by measuring BP and heart rate (HR) in freely moving conscious WT and apo-sGC mice by telemetry, and in restrained mice by tail-cuff. Systolic BP (SBP) was higher in conscious apo-sGC mice than in WT mice (Fig. 3c,d,f). HR did not differ between apo-sGC and WT mice (Fig. 3e,f). Administration of the NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME) in vivo increased BP and decreased HR in WT but not in apo-sGC mice (Fig. 4a, Supplementary Fig. 4a, 5a,b and Supplementary Table 3). Similarly, in vivo administration of the exogenous NO donors DETA-NO, an NO-donor with a half-life of 20 h at 37 °C, and Cinaciguat, an NO-donor with a half-life of <2 min at 37 °C, decreased BP and increased HR in WT but not in apo-sGC mice (Fig. 4b,c, Supplementary Fig. 4b,c, 5c–f and Supplementary Tables 4 and 5).

To further assess how the presence of apo-sGC affects the ability of NO to induce vasorelaxation, we performed vessel reactivity studies on aortic rings isolated from WT and apo-sGC mice. In accordance with the impaired cardiovascular effects of
NO in apo-sGC mice in vivo, acetylcholine, SNP, S-Nitroso-N-acyetylpenicillamine and NO gas-dependent relaxation were abolished in apo-sGC aortic rings (Fig. 5a–d). Taken together, these data demonstrate that NO-responsive sGC is required for NO to induce vasorelaxation and lower BP.

Haemodynamic effects of sGC stimulators versus activators. We then addressed whether loss of sGC haem affects the ability of BAY 41-2272 to modulate BP and HR. In vivo administration of BAY 41-2272 was associated with a BP decrease in WT mice but not in apo-sGC mice (Fig. 4d, Supplementary Fig 4d, 6c,d and Supplementary Tables 6 and 7). Similarly, the vasorelaxing effect of BAY 41-2272 on WT isolated aortic rings was greatly attenuated in aortic rings of apo-sGC mice (IC$_{50}$ ≈ 35 nmol l$^{-1}$ and 1112 nmol l$^{-1}$, respectively; Fig. 5e).

In contrast, in vivo administration of cinaciguat decreased BP and increased HR in both apo-sGC mice and WT mice (Fig. 4e, Supplementary Fig. 4e, 6e–f and Supplementary Tables 6 and 7). In fact, the BP-lowering effect of cinaciguat in apo-sGC mice was significantly greater (Fig. 4e) and longer lasting (Supplementary Fig. 7) than in WT mice. In addition, cinaciguat decreased BP in apo-sGC mice at concentrations that did not affect BP in WT mice (Supplementary Fig. 7). Furthermore, the IC$_{50}$ values for cinaciguat-induced ex vivo relaxation of precontracted aortas were threefold lower in apo-sGC mice than in WT mice (IC$_{50}$ ≈ 0.2 nmol l$^{-1}$ and 0.7 nmol l$^{-1}$, respectively; Fig. 5f). Together, our results suggest that sGC activators like cinaciguat but not sGC stimulators like BAY 41-2272 activate apo-sGC in vivo. In addition, the observation that cinaciguat can modulate vasorelaxation and BP in WT mice suggests that even in healthy mice, a subset of the available sGC pool is haem-free and responsive to sGC activators.

Reduced lifespan and altered morphology of apo-sGC mice. Apo-sGC mice are viable but have a reduced lifespan, and display gastrointestinal (GI) abnormalities and growth retardation. Other strains of mice deficient in key enzymes in the NO/sGC/cGMP pathway have a shorter lifespan than WT mice.$^{20-22}$ Similarly, we observed a reduced lifespan in apo-sGC mice compared with WT and HE littermates (Fig. 6a). In addition, weight and size of apo-sGC were consistently smaller than that of WT littermates (Fig. 6b). Anatomical observation of apo-sGC mice revealed reduced fat mass (Supplementary Fig. 8a–c), signs of pyloric enlargement (Supplementary Fig 8a–c), gastric atrophy (Fig. 6b) and reduced body weight (Supplementary Fig. 8a). We assessed for malnutrition or lack of appetite in apo-sGC mice by monitoring food intake (Supplementary Fig. 9a), production of faeces (Supplementary Fig. 9b) and serum levels of fructosamine, glucose and triglycerides (measure of metabolic function). Intriguingly, growth retardation in apo-sGC mice occurred despite a significantly increased food intake (Supplementary Fig. 9a). Serum levels of fructosamine (Fig. 6e), but not glucose or triglycerides (Fig. 6c,d), were lower in apo-sGC mice than in WT mice. These results suggest that growth retardation in apo-sGC mice is not due to malnutrition or malabsorption.

Apo-sGC mice are not protected against systemic TNF shock. Administration of a dose of TNF, previously determined to be lethal for WT mice, induced hypotension (Fig. 7a and Supplementary Fig.10) and bradycardia (Fig. 7b) in both WT and apo-sGC mice. During the first 30 min after TNF administration, the decrease in BP was less pronounced in apo-sGC mice than in WT mice (Fig. 7a and Supplementary Fig. 10, insert). The TNF-induced mortality was similar in WT and apo-sGC mice in a

Figure 2 | Characterization of WT and apo-sGC in CHO cells. (a) cGMP readout cells were co-transfected with WT-sGCα1 in combination with the WT sGCβ1-subunit or the mutant sGCβ1T105S-subunit of sGC to generate WT- and apo-sGC, respectively. Baseline activity of WT-sGC (WT) and apo-sGC (KI). *P < 0.01; unpaired t-test. (b–e) Activation pattern of WT-sGC (b,c) and apo-sGC (d,e) incubated with increasing concentrations of cinaciguat alone (■, ■), increasing concentrations of cinaciguat in combination with a fixed concentration of 10 μM ODQ (□, □), increasing concentrations of BAY 41-2272 alone (▲, ▲), or increasing concentrations of BAY 41-2272 in combination with a fixed concentration of DEA/NO (∆, ∆). Enzyme activity is represented as relative light units (RLUs). Data are mean ± s.e.m. from 5 to 7 independent experiments performed in quadruplicate, statistical analysis by Student’s t-test.
C57BL/6J background, and even increased in apo-sGC mice in a 129S7 background (Fig. 7c,d). Together, these findings demonstrate that NO-induced sGC activity is not required for the cardiovascular collapse and lethality associated with TNF-induced inflammatory shock.

**Discussion**

Oxidative stress, a major risk factor for cardiovascular disease,1-3, directly impairs sGC mediated signalling through oxidation of its prosthetic haem group, resulting in the formation of haem-free sGC or apo-sGC. Apo-sGC is insensitive to activation by NO and susceptible to active degradation through the ubiquitin-proteasome pathway.4,7,12 sGC activators such as cinaciguat were designed to specifically target and activate apo-sGC4,7,12 and protect it from degradation.23. As apo-sGC is a consequence of oxidative stress, it is proposed that targeting apo-sGC and not native sGC, may specifically target diseased organs without having unwanted side effects because of ubiquitous sGC activation. Maximizing the therapeutic potential of cinaciguat and other haem-independent sGC activators requires a thorough understanding of their target, apo-sGC, on a molecular and physiological level, and of their mode of action both in vitro and in vivo. However, investigations into the specific pathological consequences of impaired sGC activity through haem-oxidation, as well as the consequences of specifically activating the oxidized/haem-free pool of sGC have been hampered by the incapacity to distinguish native, haem-containing sGC from oxidized/haem-free sGC in vivo.7,8. We report the generation and cardiovascular characterization of a viable line of apo-sGC mice, expressing a NO-resistant sGC that can be activated by haem-independent sGC activators, and identify novel aspects of the physiological role of sGC and the in vivo actions of sGC activators.
The observation that protein levels of sGC subunits are lower in tissues from apo-sGC than in WT mice confirms recent in vitro and ex vivo findings suggesting that the ferrous haem group protects sGC from degradation. Nonetheless, the finding that apo-sGC can exist in vitro illustrates that targeting oxidized sGC represents a feasible therapeutic approach in cardiovascular (and other) disorders characterized by increased oxidative stress and subsequent oxidation of sGC.

Tissue cGMP levels and sGC catalytic activity in tissue homogenates were similar in WT, HE and apo-sGC mice. When taking into account the lower sGC protein levels in apo-sGC mice than in WT mice, these results suggest that apo-sGC has a higher basal activity than the WT enzyme. Using a cGMP-reporter cell line, we confirmed the higher basal activity of overexpressed apo-sGC in vitro. These results support previously reported findings that basal activity of a haem-free mutant of sGC or of detergent-treated haem-free sGC that lacks the characteristic Soret peak at 431 nm is higher than that of WT sGC.

Together, these findings suggest that the ligand-bound haem-group acts as an endogenous inhibitor of sGC.

The lifespan of apo-sGC mice is shorter than that of WT mice but similar to that described for mice deficient in all three NOS isoforms. These data suggest that NO affects longevity in an sGC-dependent manner. Importantly, the lifespan of apo-sGC mice, with more than 90% survival at 31 days, is substantially longer than that of sGCβ1/−/− mice, with less than 10% of sGCβ1/−/− offspring surviving longer than 31 days. The difference in survival between apo-sGC mice and sGCβ1/−/− mice suggests a pivotal role for NO-independent sGC activity in determining survival and longevity in mice.

NO–sGC–cGMP signalling was previously demonstrated to be an important mediator in the relaxation of the stomach in reflex to increases in gastric pressure. Similar to observations made in NOS1/−/− and cGMP-dependent protein kinase 1/−/− (PKGI/−/−) mice, gastric enlargement, signs of pyloric constriction and a delayed GI transit time were present in apo-sGC mice. The delayed gastric enlargement in apo-sGC is therefore likely caused by pyloric constriction and delayed gastric emptying. Comparable to sGCβ1/−/− mice, an enlarged and translocated caecum was observed in apo-sGC mice. Together, these data confirm that activation of sGC by NO is necessary for normal GI function and that basal levels of cGMP produced by apo-sGC are not sufficient to fully preserve GI function and morphology. However, basal cGMP production in apo-sGC mice seems sufficient to prevent the fatal GI dysfunction observed in sGCβ1/−/− mice. It is conceivable that the observed growth retardation is secondary to abnormal GI function. However, normal triglyceride and glucose levels suggest that impaired GI function in apo-sGC mice does not result in malnutrition. It remains to be determined whether alterations in metabolism or tissue development contribute to the reduced fat mass observed in apo-sGC mice despite an increase in food uptake.

The ability of NO to inhibit platelet activation, to induce vascular smooth muscle relaxation and to lower BP is well characterized. Consistent with results in sGCβ1/−/−, sGCz1/−/− and PKGI/−/− mice, lack of NO-dependent sGC activation completely abrogated the anti-platelet and BP-lowering effects of NO. These results demonstrate that haem-containing, reduced sGC is required for NO’s effects on platelets and systemic vasorelaxation.

sGC stimulators are a novel class of molecules that stimulate the catalytic activity of sGC, and that have been successfully developed for therapeutic use in PAH. They are dependent on interaction with the sGC haem-group to activate the enzyme, and can activate sGC in a synergistic manner with NO. The ability

**Figure 4** | Cinaciguat but not NO or BAY 41-2272 decreases mean arterial pressure (MAP) in apo-sGC (KI) mice. MAP ± s.e.m. measured telemetrically in KI and WT mice 1–25 min after challenge with PBS (10 ml kg−1 IV; WT: n = 8, KI: n = 9; a, b), L-NAME (100 mg kg−1 IV; WT: n = 7, KI: n = 4; a), DETA-NO (60 mg kg−1 IV; WT: n = 7, KI: n = 9; b), PBS (10 ml kg−1 IP; WT: n = 7, KI: n = 10; c), SNP (1.5 mg kg−1 IP; WT: n = 5, KI: n = 6; c), vehicle (10 ml kg−1 IP; WT: n = 5, KI: n = 9; d), BAY 41-2772 (4 mg kg−1 IP; WT: n = 5, KI: n = 9; e), vehicle (10 ml kg−1 IV; WT: n = 7, KI: n = 7; e) or cinaciguat (300 mg kg−1 IV; WT: n = 8, KI: n = 7; e). *P < 0.05, **P < 0.01 and ***P < 0.001 compared with PBS or vehicle by residual maximum likelihood (REML) (see also Supplementary Tables 3–7).
of BAY 41-2272 to activate apo-sGC, either alone or in synergy with NO, or to relax aortic rings was severely attenuated. The residual effect of BAY 41-2272 in aortic rings of apo-sGC mice is likely due to off target effects, including its inhibitory effect on phosphodiesterases at concentrations higher than 5 \( \mu \text{mol} \text{l}^{-1} \) (refs 35,36). Similarly, administration of BAY 41-2272 decreased BP in WT but not apo-sGC mice. These results confirm the absence of haem in the apo-sGC enzyme and demonstrate that apo-sGC cannot be activated by BAY 41-2272 in vivo.

Cinaciguat, a member of a new class of haem-independent sGC activators, exclusively activates haem-free sGC by binding in the haem pocket and changing the enzyme's conformation\(^\text{14}\),\(^\text{15}\). In a cGMP reporter cell line transfected with WT sGC, ODQ, a known oxidizer and inhibitor of sGC, potentiated the ability of cinaciguat to activate sGC. In contrast, ODQ did not affect the activation profile of cinaciguat in a cGMP reporter cell line transfected with WT sGC, indicating again that apo-sGC is completely haem-free. It is noteworthy that, despite lower sGC protein levels in tissues isolated from apo-sGC mice than WT mice, IC\(_{50}\) values for cinaciguat-induced ex vivo relaxation of precontracted apo-sGC aortas were lower than those in WT aortas. In addition, cinaciguat had a more potent effect on BP in apo-sGC mice than in WT mice. Our ex vivo aortic ring experiments and in vivo BP observations validate the hypothesis that cinaciguat can activate haem-free/oxidized sGC in relevant tissues.

The observation that cinaciguat also has effects on sGC activation, vasorelaxation and BP in WT cellular systems, WT organ baths and WT mice, respectively, is an indication that in normal circumstances, a subset of the available pool of sGC is haem-free. Consequently, sGC activators may also impact healthy tissue. Whether this is due to the presence of low levels of oxidative stress in healthy organisms or whether the interaction of the haem group with sGC is dynamic in vivo remains unresolved. In the latter case, at higher concentrations, cinaciguat might be able to compete with the haem group for binding to sGC as was suggested previously\(^\text{8}\). When attempting to estimate the amount of apo-sGC in healthy tissues, it should be stressed that the correlation between sGC activity, the amount of cGMP produced and the resulting physiological response is weak. For example, in sGC\(_z\text{1}\)\(^{-/}\) mice, the sGC\(_z\text{2}\)\(\beta\)1 isoform, expressed at 20-fold lower levels than sGC\(_z\text{2}\)\(\beta\)1 in vascular tissue, was sufficient to mediate a robust vasorelaxing response and BP lowering effect of NO, in the absence of a measurable increase in cGMP content\(^\text{32,33}\). More importantly, by titrating the dose of cinaciguat in vivo, we were able to observe a reasonable therapeutic window in which beneficial properties of reactivation of haem-oxidized sGC might be achieved, while avoiding unwanted systemic side effects. Our observations imply that careful dosing and titration might be necessary in developing therapeutic approaches to attain specificity for diseased organs.

Together, these results demonstrate the validity of the concept that loss of the haem of sGC in vivo, suggested to occur during conditions of increased oxidative stress\(^\text{4}\), results in elevated NO levels in vivo. In this way, sGC presents advantages as a therapeutic target for pathologies associated with oxidative stress for two reasons. First, it is downstream from NOS enzymes, which were shown to exert other functions besides sGC activation and which produce free radicals themselves under conditions of oxidative stress. Second, sGC is a target of oxidative damage and can be reactivated by haem-independent sGC activators like cinaciguat. The apo-sGC mouse model provides a unique experimental platform to directly...
study both the effects of the increased presence of oxidized or haem-free sGC, and the therapeutic ability of sGC activators.

Mortality associated with systemic inflammatory response syndromes (SIRS), such as the cytokine storm syndrome and sepsis, is the highest in the subset of patients who develop shock. The pathophysiology of the first stages of SIRS, including infection, and immune and inflammatory reactions, is quite heterogeneous, with mechanisms ranging from immune paralysis to cytokine storm. However, the development of the cardiovascular collapse in SIRS has generally been considered to depend on a few common mechanisms, of which NO-sGC-cGMP signalling is a major culprit in vasodilation, distributive shock and cardiodepression. In both animal models and patients, NO produced by inducible NOS2 was implicated in both vasodilation and cardiodepression during shock. Unfortunately, in subsequent clinical trials, inhibition of NOS was found to increase BP in sepsis patients but failed to improve survival. In fact, treatment with non-isoform-specific NOS inhibitors was associated with higher mortality. Further research identified the existence of NOS-dependent protective cardiovascular effects in SIRS. We previously reported that mice deficient in sGCα1 (sGCα1−/− mice) are sensitized to the cardiac dysfunction and mortality associated with inflammatory shock (both endotoxin-induced and TNF-induced shock), suggesting that sGCα1β1-derived cGMP is cardioprotective in murine inflammatory shock models. In addition, we have recently shown that the haem- and NO-independent sGC activator BAY 58-2667 (Cinaciguat), can improve organ function and survival during lethal endotoxemia when given in the appropriate treatment window. Together, these considerations frame the ongoing debate on the exact role, be it detrimental or protective, of NO-sGC-cGMP signalling in the cardiovascular collapse during shock.

The availability of NO-insensitive apo-sGC mice facilitates research into testing the hypothesis whether the cardiovascular collapse in SIRS depends on NO-dependent sGC activation. To do so, we opted for a TNF-induced SIRS model characterized by a marked increase in systemic NO levels, in which the cardiovascular collapse is a most prominent feature, and which mimics the human situation in its cardiovascular aspects. Using a downstream effector as a challenge instead of an infectious challenge avoids as much as possible that the observed consequences of modulation of the NO-sGC-cGMP pathway...
we would be due to interference with the effects of this pathway on infection control and on the regulation of the generation of an immune and inflammatory response itself, rather than on the effects of NO-sGC-cGMP on the cardiovascular system. Indeed, NO-sGC-cGMP signalling has also effects outside the cardiovascular system, such as in infection control and in the regulation of the generation of an immune and inflammatory response. Administration of a lethal dose of TNF induced similar hypotension and bradycardia in WT and apo-sGC mice. Only in the first 30 min after TNF administration, a time at which NO is derived from NOS3 rather than NOS2, the decrease in BP was more pronounced in WT than in apo-sGC mice. This suggests that the early, NOS3-derived effect of TNF on BP is mediated in part by the sGC/cGMP pathway, whereas the later effects are sGC independent. The TNF-induced mortality was similar in WT and apo-sGC mice on a C57Bl/6J background, and even higher in apo-sGC mice than in WT mice on a 129S7 background. Even though a poor nutritional status has been associated with increased mortality in inflammatory shock52, it is unlikely that malnutrition contributes to the increased mortality in apo-sGC mice taking in to account the normal triglyceride and glucose levels of apo-sGC mice. These results indicate that NO-sGC-dependent signalling is not required for cardiovascular collapse or for mortality associated with inflammatory shock. Together with recent observations that excessive production of systemic NOS2-derived NO is not necessarily associated with haemodynamic collapse53, our observations in apo-sGC mice challenge the prevailing paradigm of the central and crucial role of NO/sGC signalling in inflammatory shock. An alternative mechanism leading to septic shock might be the direct oxidative activation of PKG1 as proposed recently5. These observations do not exclude protective or deleterious involvement of NO-sGC-dependent signalling in the antimicrobial or inflammatory aspects of the pathophysiology of sepsis but only imply that NO-sGC signalling is not the pathway resulting in cardiovascular collapse.

In conclusion, this paper describes the cardiovascular phenotype of a novel mouse model that allows us to distinguish between sGC-dependent and sGC-independent effects of NO and between haem-dependent and haem-independent effects of sGC. Our results highlight the importance of sGC as the primary receptor for NO in cardiovascular physiology, and identify an important role for haem-independent activity of sGC in determining survival and longevity. In addition, we demonstrated that, in a model of TNF-induced systemic shock, NO/sGC/cGMP signalling is not responsible for the prolonged refractory hypotension or for mortality. The data presented here illustrate the therapeutic potential of compounds able to activate apo-sGC in setting of cardiovascular disease, including systemic hypertension, providing a solid scientific ground for the further development of this new class of drugs.

Methods

Generation of apo-sGC mice. The sGCβ1-targeting vector was constructed using a 10.5-kb genomic DNA contig picked up by screening of a 129SvJ lambda FIX II mouse genomic library (Stratagene). A targeting vector containing a 3-kb 3’ and a 4.1-kb 5’ flanking homology, a positive, loxP flanked (neomycin-resistance cassette, Neo’), and a negative (thymidine kinase cassette, TK) selection marker was constructed, in which the histidine residue at position 105, located in exon 5, was mutated to phenylalanine (Supplementary Fig. 1). Five other silent mutations were introduced as well. The mutations were introduced using the Transformer Site-Directed Mutagenesis Kit (Clontech Laboratories, Inc.). Targeting was applied...
in a 129SvEv mouse embryonic stem cell line and 263 G418-resistant clones were selected from the respective lines. Correct homologous recombination was confirmed through Southern blot (Supplementary Fig. 1b, c) and multiple integration events were ruled out by PCR (Supplementary Fig. 1d). One positive clone was expanded and subjected to Cre-mediated deletion of the neomycin cassette by transient transfection with the Cre-expression plasmid pCAGGS-Cre. G418-sensitive clones were selected and screened for successful deletion of the neo cassette through Southern blot (Supplementary Fig. 1b, c) and PCR (Supplementary Fig. 1d). In vitro Cre-Lox-mediated deletion of the Neo cassette after transfection of 129SvEv embryonic stem cells was verified by Southern blot using probes located at the 5' and 3' end of the construct, and by PCR (primers: P1: 5'-GAACCGACCGAAGGATACG-3'; P2: 5'GAAAGCCTGCGCAGATC-3').

Animals. Mice were bred and maintained in specific pathogen-free conditions in the animal facility of IARC/IB1, Gent. Mice were housed in temperature- and humidity-controlled conditions at 21°C and 40–65% relative humidity, 14 h/day light/darkness, with ad libitum food and water. Mice were fed irradiated 'Transbreed' chow (SDS), unless stated otherwise, and regular drinking water. The genetic background of the mice is an F2 mixed background of 129SvEv x C57Bl/6J, except if stated otherwise. In all experiments, littermates were used as controls. All experiments were conform to the Belgian and European law on laboratory animal experimentation and were approved by the Local Ethical Committee of Ghent University.

Growth curve. Apo-sGC mice were fed three different rodent chows: standard diet (SNIFF), expanded diets (RM3, SDS) and a high-energy and high-nutrient diet (Biobest) (Supplementary Fig. 1c). Experiments were performed after 4 days of feeding. Food and water were removed for 24 h. At 4 days, 24 h faeces were collected and 24 h food uptake was measured for 3 control wild-type mice and 3 Apo-sGC mice. Food and water were ad libitum.

Collection and analysis of blood. Blood was collected by cardiac puncture and kept for 30 min at room temperature to promote clot formation. Serum was prepared by cold centrifugation (14,000 rpm, 30 min) using a mechanical homogenizer (Polytron PT1600E) for protein extraction. Serum glucose was determined with the EnzyChrom Triglyceride Assay Kit (BioAssay Systems) on a Cobas-Mira 6000 analyzer (Roche). Fructosamine levels were determined on a Cobas-Mira II analyzer (Roche) using the Roche reagents (Roche). Triglyceride levels were determined with the EnzyChrom Triglyceride Assay Kit (BioAssay Systems) according to the manufacturer's instructions.

Harvesting of organs. Mice were killed by cervical dislocation and organs were quickly dissected and weighed or snap frozen for immunoblot, sGC activity, cGMP concentration and RT-Q-PCR, and stored at -70°C.

Immunoblot analysis and quantification of sGC subunits. Tissue samples were pulverized at -70°C (Retsch MM301), homogenized in 1 ml ice-cold lysis-buffer (HEPES 20 mmol l-1, NaCl 350 mmol l-1, Triton X-100 0.5%, EDTA 0.5 mmol l-1, Glycerol 20%) supplemented with 1 mmol l-1 Pefabloc SC (Roche Diagnostics), 0.3 mmol l-1 Aprotinin (Roche Diagnostics), 1 mmol l-1 Leupeptin (Roche Diagnostics), 25 mmol l-1 β-glycerophosphate, 1 mmol l-1 NaVO4, 5 mmol l-1 NaF and 'complete' EDTA-free protease inhibitor cocktail (Roche), using a mechanical homogenizer (Polytron PT1600E) for protein extraction. Samples were centrifuged at 14,000 g for 20 min at 4°C. Protein extracts (brain 100 μg, lung 100 μg) were separated on a 10% SDS-polyacrylamide gel and transferred to nitrocellulose filters. sGCα1 and sGCβ1 were detected using a rabbit anti-rat antibody from Sigma (G280 and G4405, respectively, 1:500 dilution). sGCα2, a rabbit anti-human antibody from Abcam (ab24108 1:500) was used. Immunoblotting with monoclonal mouse anti-human actin (MP Biomedicals, 1:2000) was performed to correct for equal loading. Detection and analysis were performed with the Odyssey system (Odyssey 2.1.12, Li-Cor Biosciences) using fluorescent reagents (Cy2, Cy3 and Cy5) and the Odyssey Infrared Imaging system (Li-Cor). Films were exposed at room temperature for 2–3 h. Films were scanned on a Typhoon 9400 (GE Healthcare) and analyzed using ImageQuant TL software.

sGC enzyme activity. To measure sGC enzyme activity, lung, aorta, brain and left ventricle tissues were harvested and homogenized in buffer containing 50 mmol l-1 HEPES (pH 7.5), 1.5 mmol l-1 MgCl2, 0.5 mmol l-1 1- methylisobutylxanthine, 7.5 mmol l-1 creatine phosphate, 0.2 mg ml-1 creatine phosphokinase, 1 mmol l-1 L-NAME and 1 mmol l-1 5’-GTP with or without 10 μmol l-1 DETA-NO, 100 μmol l-1 cinnacigut or 1 mmol l-1 Bay 41-2272. The reaction was terminated by adding 0.9 ml of 0.05 ml l-1 HCL. cGMP was measured using a commercial radioimmunoassay kit (GE Healthcare). sGC enzyme activity is expressed as picomoles of cGMP produced per minute per milligram of protein in extract supernatant.

cGMP concentrations. Mice were dissected immediately or 10 min after intra-peritoneally (IP) injection of 60 mg kg-1 DETA-NO. Harvested organs were first powdered at 70°C (Retsch MM301) and subsequently homogenized in 1 ml ice-cold 100% ethanol. Extracts were centrifuged at 14,000 g for 10 min at 37°C. The supernatant was transferred and the pellet was washed once with 0.5 ml ice-cold 100% ethanol and centrifuged at 14,000 g for 10 min at 37°C. The total supernatant was dried under vacuum at 30°C. The pellet was redisolved in protein buffer (20 mmol l-1 HEPES, 350 mmol l-1 NaCl, 0.5 mmol l-1 EDTA, 20% glycerol, 0.5% Triton X-100, EDTA-free protease inhibitor mix), centrifuged for 10 min at 14,000g at 37°C and protein concentration of the supernatant was measured using a BCA Protein Assay Kit (Pierce). sGC activity was measured in EIA-buffer and cGMP concentrations were measured using the acetylation-protocol, of the Cyclic GMP EIA Kit (Cayman Chemical). cGMP concentration is expressed as picomole cGMP per milligram of protein.

Measurement of mRNA expression levels. Tissues were harvested, rinsed in PBS, snap frozen in liquid N2 and stored at -70°C until RNA was extracted using the RNeasy Plus Protect Mini Kit from QIAGEN according to the manufacturer’s instructions. One microgram of RNA was used in the 5′ RACE cDNA Synthesis Kit (Bio-Rad) for RT–PCR to produce cDNA using random hexamers primers. cDNA was subsequently used for relative expression quantification using the LightCycler 480 SYBR Green I Master mix (Roche Diagnostics) in a LightCycler 480 (Roche). To this end, subunit-specific primer sets were synthesized (see Supplementary Table 1) to normalize the data. The geometric mean of the two housekeeping genes, 60S ribosomal protein L13 (RPL13) and β-actin (ACTB), out of five tested genes, was calculated with the geNorm Housekeeping Gene Selection Kit ( PrimerDesign Ltd) was used. Each sample was measured in triplicate to determine the threshold cycle (Ct). For each sample, the normalization factor was calculated as the difference between the Ct of the two housekeeping genes of the sample and the mean Ct of the housekeeping genes of all samples. The level of target mRNA, relative to the mean of the reference housekeeping genes, was calculated by raising 2 to the power of [(Ct of [Ct of target - housekeeping gene normalization factor]). Data ± s.e. are plotted as relative amount versus WT male = 100%.

Characterization of WT and apo-sGC in a CHO reporter cell line. Mutagenesis of expressing WT sGC was performed using the QuikChange site-directed mutagenesis kit according to the manufacturer’s protocol. The following primer was used to perform the desired mutation: 5′-GAGTGGCCCTG TTGACACACTGC-3’. The accuracy of the mutation was verified by sequencing (Invetek).

To characterize the sGC mutant in an intracellular environment, a cGMP reporter cell was constructed based on a method reported earlier. Briefly, a CHO cell line expressing cytotoxic acid was stably transfected with a plasmid coding for the cGMP-gated ion channel CNG2 under a zoscin resistance. Thereafter, zoscin-resistant clones were characterized for a channel expression, and active site mutants were isolated. The mutated sGC was then cultured in Dulbecco’s modified Eagle’s medium pyruvate /F12 with l-glutamine (Invitrogen), 1 mmol l-1 sodium pyruvate and 50 μg ml-1 streptomycin, 2.5 μg ml-1 amphotericin B and 10% (v/v) inactivated fetal calf serum. For cGMP readout cells were seeded on 96-well microtitre plates at a density of 10,000 cells per well and were cultured for 1 day at 37°C and 3% CO2 to ensure confluent growth. Afterward, cells were co-transfected applying a transfection mixture containing 9 ng of pEG1 and 9 ng of pIplasmid, 0.12 μg of Plus reagent and 0.75 μl of LipofectAMINE (Invitrogen) in 100 μl OptiMEM serum-free medium (Invitrogen) according to the manufacturer’s protocol. After 3 h at 37°C, the transfection medium was replaced with serum-containing medium and cells were incubated for 24 h at 37°C to ensure optimal expression of WT- and mutant-sGC.

Cells were cultured and transiently transfected with WT-sGC or mutant-sGC as described above. 24 h after transfection medium was removed, and the transfected cells were incubated with calcium-free buffer ([130 mmol l-1 NaCl, 5 mmol l-1 KCl, 20 mmol l-1 HEPES, 1 mmol l-1 Na2HPO4, 1.8 mmol l-1 NaHCO3, pH 7.4] containing 0.83 μg ml-1 cedrentazine for 3 h at 37°C. For the determination of the sGC activation profile, cells were incubated with various concentrations of sGC activator,
cinaciguat or sGC stimulator, BAY 41-2272 or in the presence of 10 mmol l\(^{-1}\) SNP (1 mmol l\(^{-1}\)-10 mmol l\(^{-1}\)), S-nitroso-N-acetylpenicillamine (1 mmol l\(^{-1}\)-10 mmol l\(^{-1}\)), NO gas (10 mmol l\(^{-1}\)-0.1 mmol l\(^{-1}\)), BAY 41-2272 (1 mmol l\(^{-1}\)-1 mmol l\(^{-1}\), Alexis Biochemicals) and BAY 58-2667 (1 mmol l\(^{-1}\)-1 mmol l\(^{-1}\)) were recorded.

**Statistical analysis.** All data are shown as mean ± s.e. For pairwise analysis, Student’s \(t\) tests were used. Multiple-group comparisons were made using one- or two-way analysis of variance (ANOVA), as appropriate (Supplementary Table 2 and Table 2 for respective experiment, number of samples and statistics used). Multiple comparison was performed after obtaining a significant ANOVA F-test. Multiple testing correction was done using the Bonferroni method. \(p\) values were calculated using a nonlinear regression curve fitting model with variable slope. Student’s \(t\) tests, one- and two-way ANOVA were performed using 6.0.1 for Mac (GraphPad Software, http://www.graphpad.com).

Repeated measurements data were analysed by fitting the following linear mixed model: \(y_{ijkl} = \mu + g_i + t_j + g_i t_j + \epsilon_{ijkl} \) where \(y_{ijkl}\) is the phenotypic value of the \(i\)th individual; \(\mu\) is the mean term; \(g_i\) is the effect of the \(i\)th genotype (e.g., 1…2\(t\) and \(K\) for telemetered and sGC detectable in living cells, respectively); \(t_j\) is the effect of the \(j\)th treatment (e.g., 1…2 and \(c\) for tail-cuff data); \(\epsilon_{ijkl}\) is the effect of the \(k\)th time point and \(\epsilon\) is the residual effect, \(\epsilon_{ijkl} \sim N(0, \sigma^2)\) with \(\sigma^2\) being the residual variance. Times of measurements were equally spaced and various ways of modelling the correlation structure (uniform, autoregressive order 1 (AR1) or 2 (AR2), and antedependence order 1 and 2) were compared in the residual maximum likelihood (REML) framework as implemented in Genstat\(^{60}\). Selection of the best model fit was based on a likelihood ratio test statistic and the Akaike Information coefficient. When residuals from the analysis indicated increasing variance over time, this was modelled directly by specifying that heterogeneity is to be introduced into model. Significance of the fixed main and interaction effects was assessed by either a Wald test or a \(F\) test.

### References

1. Armitage, M. E., Wingler, K., Schmidt, H. H. H. \& La, M. Translating the oxidative stress hypothesis into the clinic: NOX versus NOS. *J. Med. Mol. Biol.* **87**, 1071–1076 (2009).

2. Rudky, O. et al. Protein kinase G oxidation is a major cause of injury during sepsis. *Proc. Natl Acad. Sci. USA* **110**, 9909–9913 (2013).

3. Murad, F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. *N. Engl. J. Med.* **355**, 2003–2011 (2006).

4. Stach, J.-P. et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. *J. Clin. Invest.* **116**, 2552–2561 (2006).

5. Zhao, Y., Schelvis, J. P., Babcock, G. T. \& Marletta, M. A. Identification of histidine 105 in the beta1 subunit of soluble guanylate cyclase as the heme ligand. *Biochemistry* **37**, 4502–4509 (1998).

6. Martinez-Ruiz, A., Cadenas, S. \& Lamas, S. Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. *Free Radical Biol. Med.* **51**, 17–29 (2011).

7. Hoffmann, L. S. et al. Fluorescence quenching makes haem-free soluble guanylate cyclase detectable in living cells. *PLoS ONE* **6**, e23596 (2011).

8. Roy, B., Mo, E., Vernon, J. \& Garthwaite, J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. *Br. J. Pharmacol.* **153**, 1495–1504 (2008).

9. Hoffmann, L. S. et al. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. *Br. J. Pharmacol.* **157**, 781–795 (2009).

10. Boerger, G. et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. *Hypertension* **49**, 1128–1133 (2007).

11. Lapp, H. et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. *Circulation* **119**, 2781–2788 (2009).

12. Ahmed, L. et al. Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. *Atherosclerosis* **218**, 431–434 (2011).

13. Ghofrani, H.-A. et al. Riociguat for the treatment of pulmonary arterial hypertension. *N. Engl. J. Med.* **369**, 330–340 (2013).

14. Evgenov, O. V. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. *Nat. Rev. Drug. Discov.* **5**, 755–768 (2006).

15. Follmann, M. et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. *Angew. Chem. Int. Ed. Engl.* **52**, 9442–9462 (2013).

16. Nguyen, H. B. et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. *Ann. Emerg. Med.* **48**, 28–54 (2006).

17. Cautels, A. Nitric oxide in shock. *Kidney Int. J.* **72**, 557–565 (2007).

18. Epstein, F. H., Landry, D. W. \& Oliver, I. A. The Pathogenesis of Vasodilatory Shock. *N. Engl. J. Med.* **345**, 588–595 (2001).
19. Wedel, B. et al. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc. Natl Acad. Sci. USA 91, 2592–2596 (1994).

20. Friebe, M., Meriga, E., Dangel, O., Lange, A. & Koelsch, D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc. Natl Acad. Sci. USA 104, 7699–7704 (2007).

21. Pfeifer, A. et al. Defective smooth muscle regulation in GMP kinase I-deficient mice. EMBO J. 17, 3045–3051 (1998).

22. Tsutsui, M., Shimokawa, H., Motishi, T., Nakashima, Y. & Yanagihara, N. Development of genetically engineered mice lacking all three nitric oxide synthases. J. Pharmacol. Sci. 102, 147–154 (2006).

23. Meurer, S. et al. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ. Res. 105, 33–41 (2009).

24. Schmidt, P. M., Schramm, M., Schröder, H., Wunder, F. & Stasch, J.-P. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J. Biol. Chem. 279, 3025–3032 (2004).

25. Martin, E., Sharma, I., Kots, A. & Murad, F. A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation. Proc. Natl Acad. Sci. USA 100, 9208–9213 (2003).

26. Desai, K. M., Sessa, W. C. & Vane, J. R. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 351, 477–479 (1991).

27. Gyruko, R., Leupen, S. & Huang, P. L. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypoaggregation and infertility. Endocrinology 143, 2774–2777 (2002).

28. Huang, P. L., Dawson, T. M., Bredt, D. S., Snyder, S. H. & Fishman, M. C. NO-independent regulatory site on soluble guanylate cyclase. Cell 75, 1273–1286 (1993).

29. Cosyns, S. M. R. et al. Heme deficiency of soluble guanylate cyclase induces gastraparesis. Neurogastroenterol. Motil. 25, e339–e352 (2013).

30. Erdmann, J. et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504, 432–436 (2013).

31. Thoonen, R., Sips, P. Y., Bloch, K. D. & Buys, E. S. Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling. Curr. Hypertens. Rep. 15, 47–58 (2013).

32. Mergia, E., Friebe, A., Dangel, O., Ruswurm, M. & Koelsch, D. Sparse guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J. Clin. Invest. 116, 1731–1737 (2006).

33. Buyuksar, Y. et al. Gender-specific hypertension and responsiveness to nitric oxide in SGCalpha1 knockout mice. Cardiovasc. Res. 79, 179–186 (2008).

34. Massberg, S. et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine monophosphate kinase I. J. Exp. Med. 189, 1255–1264 (1999).

35. Stasch, J. P. et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 410, 212–215 (2001).

36. Martin, E., Lee, Y. C. & Murad, F. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc. Natl Acad. Sci. USA 98, 12938–12942 (2001).

37. Angus, D. C. & van der Poll, T. Severe sepsis and septic shock. N. Engl. J. Med. 369, 840–851 (2013).

38. López, A. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in multiple-internal control genes. Proc. Natl Acad. Sci. USA 100, 9208–9213 (2003).

39. Vandenheede, B. et al. The soluble guanylyl cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems. PLoS ONE 8, e71305 (2013).

40. Tatsuni, T. et al. Nitric oxide-cGMP pathway is involved in endotoxin-induced contractile dysfunction in rat hearts. J. Appl. Physiol. 96, 853–860 (2004).

41. Cauwels, A. et al. Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity 13, 223–231 (2000).

42. Kumar, A. et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am. J. Physiol. 276, R265–R276 (1999).

43. Daemen-Gubbels, C. R. et al. Methylene blue increases myocardial function in septic shock. Crit. Care Med. 23, 1363–1370 (1995).

44. Kirov, M. Y. et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit. Care Med. 29, 1860–1867 (2001).

45. Knotek, M., Esson, M., Gengaro, P., Edelstein, C. L. & Schrier, R. W. Desensitization of soluble guanylate cyclase in renal cortex during endotoxemia in mice. J. Appl. Physiol. 11, 2133–2137 (2000).

46. Antoniades, J. A., Bruining, H. A. & Ince, C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxic rats. Circ. Res. 76, 418–425 (1995).

47. Kojda, G. et al. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ. Res. 78, 91–101 (1996).

48. Buyuksar, Y. et al. sGC(alpha1)(beta1)attenuates cardiac dysfunction and mortality in murine inflammatory shock models. Am. J. Physiol. Heart Circ. Physiol. 297, H654–H662 (2004).

49. Tracey, K. J. et al. Shock and tissue injury induced by recombinant human cachexin. Science 234, 470–474 (1986).

50. Parrillo, J. E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328, 1471–1477 (1993).

51. Riedemann, N. C., Guo, R.-F. & Ward, P. A. The enigma of sepsis. J. Clin. Investig. 112, 460–467 (2003).

52. Saffrey, R., Moser, A., Feingold, K. R. & Grunfeld, C. Reduced leptin levels in starvation increase susceptibility to endotoxic shock. Am. J. Pathol. 156, 1781–1788 (2000).

53. Cauwels, A. et al. TLR2 activation causes no morbidity or cardiovascular failure, despite excessive systemic nitric oxide production. Cardiovasc. Res. 100, 24–35 (2013).

54. Schooijens, L. et al. Improved generation of germine-competent embryonic stem cell lines from inbred mouse strains. Stem Cells 21, 90–97 (2003).

55. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 research0034.1-research0034.11 (2002).

56. Wunder, F. et al. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal. Biochem. 339, 104–112 (2005).

57. Cortellini, I. et al. Roles and interactions among protease-activated receptors and P2Y2/12 in hemostasis and thrombosis. Proc. Natl Acad. Sci. USA 107, 18605–18610 (2010).

58. Mills, P. A. et al. A new method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. J. Appl. Physiol. 88, 1537–1544 (2000).

59. Krege, J. H., Hodgkin, J. B., Hageman, J. R. & Smithies, O. A noninvasive computerized tail-cuff method for measuring blood pressure in mice. Hypertension 25, 1111–1115 (1995).

60. Payne, Genstat Release 12.1 Reference Manual. 3, VSN International Ltd. (2012).